Patents by Inventor Emeline Tabouret

Emeline Tabouret has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TP5, A PEPTIDE INHIBITOR OF ABERRANT AND HYPERACTIVE CDK5/P25 AS TREATMENT FOR CANCER
    Publication number: 20220009980
    Abstract: Methods of decreasing cell viability of cancer cells, increasing apoptosis of cancer cells, and treating cancer in a mammal with cancer are provided. The methods include administering (i) a polypeptide comprising an amino acid sequence with at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1, (ii) a nucleic acid molecule comprising a nucleic acid sequence encoding the polypeptide, (iii) a vector comprising the nucleic acid molecule, (iv) a recombinant cell comprising any one of (i)-(iii), and/or (v) a composition comprising any one of (i)-(iv).
    Type: Application
    Filed: November 13, 2019
    Publication date: January 13, 2022
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Zhengping Zhuang, Emeline Tabouret, Herui Wang, Harish Pant, Niranjana D. Amin
  • MMP2 AS A PREDICTIVE BIOMARKER OF RESPONSE TO ANTIANGIOGENIC THERAPY AND SURVIVAL AFTER THERAPY IN CANCER PATIENTS
    Publication number: 20150148248
    Abstract: The present invention relates to the use of matrix metalloproteinase-2 (MMP2) as a predictive biomarker of response to antiangiogenic therapy and survival after antiangiogenic therapy in cancer patients, and to related methods for predicting or monitoring the response to an antiangiogenic treatment and the survival after said treatment of a cancer patient.
    Type: Application
    Filed: May 23, 2013
    Publication date: May 28, 2015
    Inventors: Olivier Chinot, Emeline Tabouret